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OBJECTIVE—We tested whether long-term treatment with the angiotensin II receptor an-
tagonist irbesartan reduces nucleic acid oxidation in patients with type 2 diabetes and micro-
albuminuria.
RESEARCH DESIGN AND METHODS—The Irbesartan in Patients With Type 2
Diabetes and Microalbuminuria (IRMA 2) study was a 2-year multicenter randomized double-
blind trial comparing irbesartan (150 and 300 mg once daily) with placebo. We studied a
subgroup of 50 patients where urine samples were available for analysis of albumin and the
oxidatively modiﬁed guanine nucleosides 8-oxo-7,8-dihydro-29-deoxyguanosine (8-oxodG)
and 8-oxo-7,8-dihydroguanosine (8-oxoGuo).
RESULTS—During the 2-year trial, no signiﬁcant differences in 8-oxodG and 8-oxoGuo excre-
tions between placebo and irbesartan treatment were seen. 8-oxodG and albumin excretion
decreased with time (P = 0.0004 and P , 0.0001, respectively), whereas treatment-related
differences were shown for albumin excretion (P = 0.0008) only, as previously reported. Impor-
tant secondary ﬁndings were signiﬁcant associations between changes in 8-oxodG excretion and
changes in albumin excretion and glycated hemoglobin (HbA1c). During the study period,
8-oxodG excretion decreased by 3 and 26% in smokers and nonsmokers, respectively (P = 0.015),
and urinary albumin excretion decreased 22% in smokers and 58% in nonsmokers (P = 0.011).
CONCLUSIONS—Irbesartan treatment was not signiﬁcantly more effective than placebo in
reducing nucleic acid oxidation. The results indicate that DNA oxidation in diabetes patients is
reduced by various components in the treatment of diabetes where glycemic control seems to be
important and addition of angiotensin II receptor antagonists does not lead to any substantial
additional reduction. Furthermore, the reductions in DNA oxidation and albumin excretion
seem to be counteracted by smoking.
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C linical trials have consistently shownthat pharmacological blockade ofthe renin-angiotensin-aldosterone
system reduces the development of car-
diovascular morbidity and the risk of
death in diabetic patients (1,2). Excessive
oxidative stress, which arises as a result
of an imbalance between generation and
elimination of reactive oxygen species,
has been suggested to be a common patho-
genic mechanism in several complica-
tions of diabetes, and it has been shown
that treatment with inhibitors of renin-
angiotensin-aldosterone system reduces
markers of oxidative stress in patients
with diabetes (3).
The easiest and least invasive method
to assess oxidative stress in patients is the
measurement of oxidation products in
urine. Together with the F2-isoprostanes,
which measures lipid peroxidation, the
oxidized deoxyribonucleoside 8-oxo-7,
8-dihydro-2’-deoxyguanosine (8-oxodG)
is the most frequently measured urinary
marker of oxidative stress. 8-oxodG is
considered a valid biomarker of DNA
oxidation. Its propensity to mispair with
adenine and mutagenic properties are
well described. A speciﬁc, sensitive, and
reproducible methodology has been de-
veloped. Elevated levels have been dem-
onstrated in many diseases and from
many hazardous inﬂuences, and 8-oxodG
is regarded as the gold standard in this
area (4).
The ribonucleoside counterpart 8-
oxo-7,8-dihydroguanosine (8-oxoGuo)
is one of the most extensively used bio-
markers for assessment of RNA oxidation,
and in the current study, we measured
the urinary excretion of both 8-oxodG and
8-oxoGuo to assess the total systemic
oxidative stress to DNA and RNA, respec-
tively.
Studies have found that treatment
with angiotensin II receptor blockers re-
duce urinary excretion of 8-oxodG in
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
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both patients with hypertension and di-
abetes (3,5,6), but evidence from placebo-
controlled studies of the effect of long-term
angiotensin II receptor blocker treatment
on DNA or RNA oxidation are missing.
Diabetic patients with microalbumin-
uria have a 10–20 times increased risk of
nephropathy compared with diabetic pa-
tients with normoalbuminuria, and treat-
ment with the angiotensin II receptor
blocker irbesartan reduces the rate of pro-
gression to macroalbuminuria, the hall-
mark of overt diabetic nephropathy in
type 2 diabetic patients (7). Whether
this renoprotective effect of irbesartan
involves a reduction in oxidative stress is
unknown. In the current study, we inves-
tigated this further.
Because other studies have shown
differences in the rate of oxidative DNA
damage between smokers and nonsmokers
(8,9) and associations between smoking
and progression of diabetic nephropathy
(10–12), we chose to assess the effect of
smoking post hoc.
The primary aim of this study was to
determine whether long-term treatment
with the angiotensin II receptor antago-
nist irbesartan reduces DNA and RNA
oxidation in patients with type 2 diabetes
and microalbuminuria. In addition, post
hoc analyses were carried out to examine
whether smoking status had any inﬂu-
ence on changes in nucleic acid oxida-
tion and albumin excretion during the
trial.
RESEARCH DESIGN AND
METHODS—The Irbesartan in Pa-
tients With Type 2 Diabetes and Micro-
albuminuria (IRMA 2) study protocol has
been described in detail elsewhere (7). In
brief, 590 hypertensive type 2 diabetic
patients with microalbuminuria were in-
cluded in this multinational randomized
double-blind placebo-controlled study
of irbesartan (150 and 300 mg) and
were followed for 24 months. The pri-
mary outcome was time to onset of dia-
betic nephropathy, deﬁned as persistent
albuminuria in overnight specimens
with a urinary albumin excretion rate
.200 mg/min and $30% increase from
baseline level. Target trough blood pres-
sure was,135/85 mmHg 3 months after
randomization. Additional antihyper-
tensive treatment used included diuret-
ics, calcium-channel blockers (except
dihydropyridines), and b-blockers. These
agents were added if target blood pres-
sure was not reached 3 months after ran-
domization. The study was approved by
the regional ethics committees and con-
ducted in accordance with the Helsinki
Declaration.
Data ascertained for this study were
collected from a subgroup of 50 Danish
patients from the original IRMA 2 study
who were followed at the outpatient
clinic at the Steno Diabetes Center. Mea-
surements of blood pressure, weight, glo-
merular ﬁltration rate (GFR), serum
hemoglobin concentration, glycated he-
moglobin (HbA1c) concentration, urinary
albumin excretion, urinary 8-oxodG and
8-oxoGuo, and other laboratory evalua-
tions were performed at baseline and at
3, 12, and 24 months.
Blood pressure was measured with a
sphygmomanometer in the sitting posi-
tion after at least 10 min of rest. HbA1c
was measured by ion-exchange high-
performance liquid chromatography.
The hemoglobin, cholesterol, and triglyc-
eride concentrations were analyzed with
standard laboratory assays. GFR was mea-
sured after a single intravenous injection
of 5 MBq 51Cr-EDTA at 8:00 A.M. by de-
termining the radioactivity in venous
blood samples taken 180, 200, 220, and
240 min after the injection, considering
sex and body weight of the patient. The
results were standardized for 1.73 m2
body surface area.
The urinary albumin concentration
was determined by nephelometry and the
creatinine concentration in serum and
urine by the Jaffe reaction.
Spot urine samples, stored at 280°C
until analysis, were assayed in 2009 for
the oxidatively modiﬁed guanine nucleo-
sides 8-oxodG and 8-oxoGuo using ultra-
performance liquid chromatography and
tandem mass spectrometry. 8-oxodG and
8-oxoGuo were normalized against uri-
nary creatinine concentration. Chromato-
graphic separation was performed on an
Acquity UPLC system (Waters, Milford,
MA). The column used was an Acquity
UPLC BEH Shield RP18 column (1.7
mm, 2.1 3 100 mm) protected with an
in-line ﬁlter (4 3 2 mm, 0.2 mm), both
obtained from Waters.
The mass spectrometric detection
was performed on an API 3000 triple
quadrupole mass spectrometer (Sciex,
Toronto, Canada) equipped with an elec-
trospray ion source (Turbospray) oper-
ated in the positive mode. Details of the
analysis are described elsewhere (13).
Statistical analysis
Baseline characteristics were compared
using the x2 test for categorical variables
and ANOVA for continuous variables. Re-
sults are presented as mean6 SD for nor-
mally distributed variables or median
(interquartile range) for nonnormally dis-
tributed variables. Pair-wise comparisons
were performed using the paired or un-
paired Student t test or Mann-Whitney test.
Repeated-measures ANOVA models
were used to analyze the effect of inter-
vention on nucleic acid oxidation and
urinary albumin excretion. Repeated-
measures ANOVA models were also
used to analyze the effect of smoking,
where comparison of changes in urinary
8-oxodG, 8-oxoGuo, and albumin excre-
tion and other possible confounding fac-
tors (weight, blood pressure, HbA1c,
GFR, and hemoglobin) between smokers
and nonsmokers were made. Interaction
terms were added to the models to assess
interaction between smoking, time, and
irbesartan treatment (time 3 smoking 3
treatment group effect).
Linear regression models were used
to assess the relationship between changes
in urinary 8-oxodG/8-oxoGuo and changes
in diabetes-related variables and possible
confounders of oxidative stress (albumin
excretion, weight, blood pressure, HbA1c,
GFR, and hemoglobin). Interactions be-
tween treatment group and changes in al-
bumin excretion, weight, blood pressure,
HbA1c, GFR, and hemoglobin were as-
sessed by adding interaction terms to the
models. Linear regression analysis was
used to determine the relationship be-
tween baseline variables and changes in
urinary 8-oxodG and 8-oxoGuo as well.
Because of deviation from normal distri-
bution, the variables 8-oxodG, 8-oxoGuo,
and urinary albumin excretion were log-
transformed before calculation.
All statistical analyses were per-
formed using the SAS software version
9.1 (SAS Institute, Cary, NC). Statistical
signiﬁcance was deﬁned as P , 0.05. All
statistical tests were two-sided.
RESULTS—Treatment groups were
balanced with respect to baseline demo-
graphic, clinical, and biochemical char-
acteristics (Table 1). There were no
statistically signiﬁcant differences in
the use of additional hypertensive and
cholesterol-lowering treatment between
the groups (Supplementary Table 1).
Effects of irbesartan treatment
Changes in 8-oxodG, 8-oxoGuo, and
albumin excretion according to treatment
group during the study are shown in Fig. 1.
No signiﬁcant differences in 8-oxodG
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and 8-oxoGuo excretions between pla-
cebo and irbesartan treatment were seen
during the trial.
Urinary 8-oxodG excretion decreased
by 23% (P = 0.06), 12% (P = 0.1), and
18% (P = 0.01) in the placebo, 150 mg
irbesartan, and 300mg irbesartan groups,
respectively.
Analysis by repeated-measures
ANOVA showed that 8-oxodG excretion
decreased with time (time effect, P =
0.0004),whereas no signiﬁcant treatment3
time interaction was seen (treatment3 time
effect, P = 0.46), reﬂecting no treatment-
related differences in the rate of change
over time (Fig. 1A). No effect of time or
treatment on 8-oxoGuo excretion was
shown (Fig. 1B).
Albumin excretion decreased during
the study period (time effect, P, 0.0001)
and a signiﬁcant treatment 3 time in-
teraction was shown for urinary albumin
excretion (treatment 3 time effect, P =
0.0008), reﬂecting treatment-related dif-
ferences in the rate of change during the
trial, where the albumin excretion de-
creased by 16, 33, and 71% in the pla-
cebo, 150 mg irbesartan, and 300 mg
irbesartan groups, respectively (Fig. 1C).
Post hoc analyses
Associations between nucleic acid ox-
idation and other variables. Simple re-
gression analysis was used to evaluate the
relationship between changes in nucleic
acid oxidation and changes in urinary
albumin excretion, weight, blood pres-
sure, HbA1c, GFR, and hemoglobin
(Supplementary Table 2).
The combined data of all the subjects
showed signiﬁcant positive association
(R2 = 0.18, P = 0.014) between percentage
changes in 8-oxodG excretion and urinary
albumin excretion, signiﬁcant positive as-
sociation (R2 = 0.18, P = 0.015) between
the percentage changes in 8-oxodG ex-
cretion and HbA1c, and signiﬁcant nega-
tive association (R2 = 0.13, P = 0.04)
between percentage changes in 8-oxodG
excretion andweight over the 2-year study
period. There were no signiﬁcant associa-
tions between changes in 8-oxoGuo and
changes in urinary albumin excretion,
weight, blood pressure, HbA1c, GFR, and
hemoglobin.
Possible effect modiﬁcation by the
variables urinary albumin excretion,
weight, blood pressure, HbA1c, GFR,
and hemoglobin were assessed in the
interaction analyses. For changes in 8-
oxodG and 8-oxoGuo excretion, no in-
teractions between treatment group and
changes in the above-mentioned variables
were found (data not shown).
Signiﬁcant associations between per-
centage changes in 8-oxodG excretion
and the baseline values of 8-oxodG, HDL
cholesterol, and age were found. Greater
8-oxodG excretion (R2 = 0.26, P = 0.002),
HDL cholesterol (R2 = 0.31, P = 0.0008),
and age (R2 = 0.14, P = 0.03) at baseline
were related to greater reduction in 8-
oxodG excretion during the trial (Sup-
plementary Table 2).
Effects of smoking. Effects of time and
smoking on urinary 8-oxodG, 8-oxoGuo,
and albumin excretions are shown in
Fig. 2. At baseline, there were no signi-
ﬁcant differences in albumin (P = 0.35),
8-oxodG (P = 0.10), and 8-oxoGuo (P =
0.41) excretions between smokers and
nonsmokers.
Regardless of treatment regimen,
both the excretion of 8-oxodG and uri-
nary albumin showed signiﬁcant group3
time interactions, reﬂecting differences in
the rate of change during the trial between
smokers and nonsmokers. During the
2-year study period, 8-oxodG excretion
decreased by 3% in smokers and 26% in
nonsmokers (smoking group 3 time
effect, P = 0.015) (Fig. 2A). Urinary albu-
min excretion decreased 22% in smokers
and 58% in nonsmokers (smoking group3
time effect, P = 0.011) (Fig. 2C).
No signiﬁcant difference in change in
urinary 8-oxoGuo between smokers and
nonsmokers was shown. Figure 2B gives
an impression of a difference between
smokers and nonsmokers, where smok-
ers had an increase and nonsmokers a
decrease in 8-oxoGuo excretion during
the trial, but a signiﬁcant difference could
not be shown, even when including only
baseline and 2-year measurements in the
analysis (smoking group3 time effect, P =
0.10; baseline + 2-year smoking group 3
time effect, P = 0.08).
No interaction between smoking,
time, and irbesartan treatment (time 3
smoking 3 treatment group effect) was
shown for albumin, 8-oxoGuo, and 8-
oxodG excretions (data not shown).
When treatment interaction was included
in the analysis, the differences between
smokers and nonsmokers were still signif-
icant for both 8-oxodG (smoking group3
time effect,P=0.03) and albumin excretion
(smoking group3 time effect, P = 0.02).
There were no signiﬁcant differences
in any of the baseline variables between
smokers and nonsmokers, and changes in
weight, blood pressure, HbA1c, GFR, and
hemoglobin during the trial did not differ
between the two groups (data not shown).
CONCLUSIONS—Our study demon-
strates a reduction of the urinary excre-
tion of 8-oxodG during the 2-year trial
period in 50 type 2 diabetic patients with
microalbuminuria. However, there was
no signiﬁcant effect of treatment with
Table 1—Baseline characteristics of the patients
Placebo 150 mg irbesartan 300 mg irbesartan
n 17 16 17
Sex (M/F) 13/4 15/1 14/3
Age (years) 60 (54–66) 58 (53–67) 55 (50–62)
Smokers (%) 6 (35) 9 (56) 5 (29)
Weight (kg) 84.8 6 14.1 91.8 6 9.5 87.5 6 14.7
BMI (kg/m2) 27.2 (26.8–29.6) 28.4 (27.1–30.4) 29.6 (25.1–31.4)
Known diabetes duration (years) 6 (3–13) 8.5 (6–12) 9 (4–12)
Systolic blood pressure (mmHg) 155 6 15 156 6 15 156 6 19
Diastolic blood pressure (mmHg) 88 6 7 91 6 11 89 6 9
Urinary albumin excretion (mg/min) 63 (39–81) 45 (25.5–85.5) 51 (39–109)
GFR (mL/min per 1.73 m2) 107.4 6 27.7 115.6 6 20.5 116.6 6 21.2
HbA1c (%) 7.1 6 1.5 6.9 6 1.3 6.8 6 1.5
Hemoglobin (mmol/L) 8.9 (8.6–9.2) 9.2 (9.0–9.6) 9.1 (8.4–9.3)
Cholesterol (mmol/L) 5.56 (5.04–5.90) 5.61 (5.02–6.31) 5.59 (5.04–5.92)
LDL cholesterol (mmol/L) 3.21 (3.08–3.57) 3.44 (2.48–3.67) 3.18 (2.77–3.70)
HDL cholesterol (mmol/L) 1.06 (0.96–1.22) 1.03 (0.83–1.32) 1.11 (1.01–1.40)
Triglycerides (mmol/L) 1.78 (1.46–2.86) 2.04 (1.46–3.78) 2.31 (1.24–3.21)
Serum creatinine (mmol/L) 97 (88–106) 97 (88–102) 88 (80–97)
8-oxodG (nmol/mmol creatinine) 2.10 (1.76–3.05) 1.92 (1.47–2.20) 2.59 (1.64–3.14)
8-oxoGuo (nmol/mmol creatinine) 3.63 (2.70–4.38) 2.86 (2.45–3.84) 4.01 (2.99–5.08)
Data are means6 SD or median (interquartile range) unless otherwise indicated. NS between all treatment groups.
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irbesartan on 8-oxodG excretion com-
pared with placebo treatment.
In previous studies, signiﬁcant reduc-
tions in 8-oxodG excretion were shown
after short-term treatment with candesar-
tan for 12 weeks in 64 patients with
essential hypertension (5) and with can-
desartan/valsartan for 8 weeks in 33 type
2 diabetic patients with nephropathy (3).
Miyashita et al. (6) demonstrated a signif-
icant reduction of urinary excretion of
8-oxodG after 12 months of olmesartan
treatment in 35 type 2 diabetic patients
with hypertension.
Ogawa et al. (3), Dohi et al. (5), and
Miyashita et al. (6) did not ﬁnd signiﬁcant
reductions in 8-oxodG excretion in the
comparison groups (calcium-channel
blocker group, control group, and tri-
chlormethiazide group), but none of the
studies included comparison with a pla-
cebo group, and tests of signiﬁcance of the
differences between the groups were only
performed in one study.
We assessed confounders by identi-
fying associations between 8-oxodG and
8-oxoGuo excretions and other measured
variables, and by performing analysis of
interactions between treatment group
and changes in the variables urinary
albumin excretion, weight, blood pres-
sure, HbA1c, GFR, and hemoglobin. No
important confounders were identiﬁed in
these analyses.
The fact that 8-oxodG excretion was
reduced in a similar degree in irbesartan
and placebo treatment indicates that the
shown reduction in DNA oxidation is
most likely induced by other factors in the
pharmacological or nonpharmacological
treatment of diabetes. We found a signif-
icant association between change in 8-
oxodG excretion and change in HbA1c,
which suggests that glycemic control is
important regarding the reduction in
DNA oxidation. Reduction in HbA1c was
associated with a reduction in 8-oxodG
excretion rate, reﬂecting diminished
DNA oxidation, and this association was
shown in other studies (14–17). To ex-
plain the association between hyper-
glycemia and DNA oxidation, several
mechanisms have been suggested. One
possible mechanism is hyperglycemia-
induced mitochondrial reactive oxygen
species production, which in turn leads
to induction of DNA damage (18,19).
As previously shown in the original
IRMA 2 study (7) and in the Microal-
buminuria Reduction With Valsartan
(MARVAL) study (20), treatment-related
differences in the rate of change in urinary
albumin excretionduring the trialwas dem-
onstrated in this study, where irbesartan
treatment led to a greater reduction in albu-
min excretion than placebo.
The reduction of albumin excretion
rate was shown to be associated with a
reduction in 8-oxodG excretion in this
Figure 1—Change in 8-oxodG (A), 8-oxoGuo (B), and albumin excretion (C) in patients (n = 50)
according to treatment group (placebo [n = 17], 150 mg irbesartan [irb] [n = 16], and 300 mg
irbesartan [n = 17]). A: Time effect: P = 0.0004; treatment3 time effect: P = 0.46. B: Time effect:
P = 0.87; treatment3 time effect: P = 0.11.C: Time effect: P, 0.0001; treatment3 time effect: P =
0.0008. Values are geometric means. creat, creatinine; UAE, urinary albumin excretion.
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study, and this positive association was
also shown by Ogawa et al. (3)
This relationship between albumin and
8-oxodG excretion is indeed noteworthy
considering that albumin excretion is
currently the best available noninvasive
means of following the course of kidney
disease in nonproteinuric diabetic patients
(21) and is an independent predictor of
increased risk for cardiovascular mor-
bidity and mortality in patients with di-
abetes and hypertension, as well as in the
general population (22).
Whether albumin excretion and ex-
cretion of 8-oxodG express the same,
different, or overlapping pathophysiolog-
ical mechanisms in diabetes is unknown.
As albumin excretion is considered to
primarily reﬂect renal damage and 8-
oxodG excretion expresses the whole-
body DNA oxidation, it seems likely that
8-oxodG excretion contains additional
pathophysiological information. This
leaves open the possibility that 8-oxodG
excretion could be used as a supplement
to albumin excretion in diabetes care. The
main question in this context is whether
patients experiencing both reductions in
8-oxodG and albumin excretion have a
better prognosis than patients with re-
duction in albumin excretion but with no
reduction in 8-oxodG excretion. This
question must be addressed on a larger
scale, which underlines the relevance of
large-scale studies evaluating the pre-
dictive role of changes in 8-oxodG ex-
cretion for morbidity and mortality in
diabetes.
Elevated 8-oxodG excretion, HDL
cholesterol, and age at baseline were
associated with greater reduction in 8-
oxodG excretion during the trial. HDL
cholesterol has been shown to be a pre-
dictor of progression to overt nephropathy,
independently of the presence of micro-
albuminuria or hypertension, where higher
levels of HDL cholesterol are associated
with a lower risk of nephropathy (23).
That high levels of HDL cholesterol are
associated with greater reductions in 8-
oxodG leaves open the possibility that
DNA oxidation could play a role in the
reduced risk of nephropathy at higher
HDL cholesterol levels. This association
should be investigated further for con-
ﬁrmation.
A signiﬁcant difference in the change
in 8-oxodG excretion and urinary albu-
min excretion between smokers and non-
smokers was seen. Nonsmokers had a
greater reduction in both 8-oxodG excre-
tion and albumin excretion during the
trial period.
These results are in accordance with
earlier studies of the relationship be-
tween smoking and development of ne-
phropathy in type 2 diabetes, where
smoking promotes the onset and pro-
gression of nephropathy (10–12). Smok-
ing has also been shown to exacerbate
Figure 2—Change in 8-oxodG (A), 8-oxoGuo (B), and albumin excretion (C) in patients (n = 50)
according to smoking status (smokers [n = 20], nonsmokers [n = 30]). A: Time effect: P = 0.002;
smoking group3 time effect: P = 0.015. B: Time effect: P = 0.99; treatment3 time effect: P = 0.10.
C: Time effect: P, 0.0001; smoking group3 time effect: P = 0.011. Values are geometric means.
creat, creatinine; UAE, urinary albumin excretion.
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markers of kidney failure, such as micro-
albuminuria (24,25), and smoking ces-
sation has been shown to reduce the
progressive damage to the kidneys in
type 2 diabetes (11).
Our results indicate that smoking
status is not only a predictor of nephrop-
athy but also an important predictor of
the change in DNA oxidation in type 2
diabetic patients with microalbuminuria.
The statistical power of our analysis is
limited by the relatively small sample size.
However, the size of our population is
sufﬁcient to show signiﬁcant reductions
in 8-oxodG and albumin excretion and
to show the signiﬁcant difference in al-
bumin excretion between placebo and
irbesartan treatment. Given the three-
group design, our study had 93% power
to detect an effect size of 0.56 in the
change in albumin excretion, which is
considered to be a large effect. The effect
size of the change in 8-oxodG excretion
was in our study estimated to be only
0.14, and with such a small effect size, it
would require a total sample size of 450
to achieve 80% power. This means that
if a difference in the change in 8-oxodG
excretion between the groups actually
exists, it is too small to be detected here,
since our study was not designed to detect
such small differences.
Another important limitation of our
study is that no information regarding
changes in smoking patterns was avail-
able. We cannot rule out that changes in
smoking habits during the trial could be
a confounder regarding treatment effects.
In this study, we conclude that patients
who were smokers at baseline had a
smaller reduction in albumin and 8-
oxodG excretion than nonsmokers, but
the effect of smoking reduction/cessation
could not be investigated.
Despite the limitations described
above, strengths that distinguish the cur-
rent evaluation from previous studies are
that our study has the beneﬁt of being
a placebo-controlled trial and having
a longer observation period than previ-
ous studies of the relationship between
renin-angiotensin-aldosterone system inhi-
bition and DNA oxidation.
In summary, in patients with type 2
diabetes and microalbuminuria, long-
term treatment with the angiotensin II
receptor antagonist irbesartan did not
lead to a greater reduction in urinary
excretion of nucleic acid oxidation mark-
ers than placebo treatment. Post hoc
analyses showed signiﬁcant associations
between changes in 8-oxodG excretion
and changes in albumin excretion and
HbA1c and a greater reduction in both the
urinary excretion of the DNA oxidation
marker 8-oxodG and albumin in non-
smokers than in smokers.
These results indicate that DNA oxi-
dation in diabetic patients is reduced by
various factors in the diabetes treatment,
where glycemic control seems to be im-
portant, and addition of angiotensin II
receptor blockers does not have a sig-
niﬁcant effect on nucleic acid oxidation.
Furthermore, the reductions in DNA ox-
idation and albumin excretion seem to be
counteracted by smoking.
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